CN114423759A - 稠合杂芳基类衍生物、其制备方法及其在医药上的应用 - Google Patents

稠合杂芳基类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN114423759A
CN114423759A CN202080065835.9A CN202080065835A CN114423759A CN 114423759 A CN114423759 A CN 114423759A CN 202080065835 A CN202080065835 A CN 202080065835A CN 114423759 A CN114423759 A CN 114423759A
Authority
CN
China
Prior art keywords
compound
group
pharmaceutically acceptable
acceptable salt
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080065835.9A
Other languages
English (en)
Other versions
CN114423759B (zh
Inventor
张晓敏
胡伟民
贺峰
白昌
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN114423759A publication Critical patent/CN114423759A/zh
Application granted granted Critical
Publication of CN114423759B publication Critical patent/CN114423759B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

本公开涉及稠合杂芳基类衍生物、其制备方法及其在医药上的应用。特别地，本公开涉及通式(I)所示的稠合杂芳基类衍生物、其制备方法及含有该衍生物的药物组合物，以及其作为ATX抑制剂的用途，和其在制备用于治疗癌症或纤维变性疾病或病症的药物中的用途。其中通式(I)的各取代基同说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (33)

  1. PCT国内申请，权利要求书已公开。
CN202080065835.9A 2019-10-25 2020-10-23 稠合杂芳基类衍生物、其制备方法及其在医药上的应用 Active CN114423759B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201911021093 2019-10-25
CN2019110210935 2019-10-25
CN202010360545 2020-04-30
CN2020103605459 2020-04-30
CN202010484128 2020-06-01
CN2020104841285 2020-06-01
PCT/CN2020/123072 WO2021078227A1 (zh) 2019-10-25 2020-10-23 稠合杂芳基类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN114423759A true CN114423759A (zh) 2022-04-29
CN114423759B CN114423759B (zh) 2023-10-20

Family

ID=75619672

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080065835.9A Active CN114423759B (zh) 2019-10-25 2020-10-23 稠合杂芳基类衍生物、其制备方法及其在医药上的应用

Country Status (3)

Country Link
CN (1) CN114423759B (zh)
TW (1) TW202128686A (zh)
WO (1) WO2021078227A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493453A (zh) * 2020-04-07 2021-10-12 江苏恒瑞医药股份有限公司 稠合芳香环类衍生物、其制备方法及其在医药上的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4367112A1 (en) 2021-07-09 2024-05-15 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026326A1 (en) * 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
CN101501035A (zh) * 2006-08-08 2009-08-05 中外制药株式会社 作为p13k抑制剂的嘧啶衍生物及其用途
JP2010090075A (ja) * 2008-10-10 2010-04-22 Taisho Pharmaceutical Co Ltd インドール又はインドリン誘導体
CN103588771A (zh) * 2013-01-15 2014-02-19 苏州云轩医药科技有限公司 具有刺猬通路拮抗剂活性的嘧啶类抗肿瘤化合物
WO2014160177A2 (en) * 2013-03-13 2014-10-02 Exelixis, Inc. Quinazoline inhibitors of pi3k
WO2016123151A1 (en) * 2015-01-26 2016-08-04 University Of Washington Bumped kinase inhibitor compositions and methods for treating cancer
CN107245074A (zh) * 2017-06-20 2017-10-13 牡丹江医学院附属红旗医院 用于治疗脑梗死的化合物及其制备方法
CN109476664A (zh) * 2017-05-17 2019-03-15 乐高化学生物科学股份有限公司 作为自分泌运动因子抑制剂的新型化合物和包含其的药物组合物
CN109790156A (zh) * 2016-07-04 2019-05-21 苏州开拓药业股份有限公司 具有刺猬通路拮抗剂活性的手性杂环化合物及其制备方法和应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101501035A (zh) * 2006-08-08 2009-08-05 中外制药株式会社 作为p13k抑制剂的嘧啶衍生物及其用途
WO2009026326A1 (en) * 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
JP2010090075A (ja) * 2008-10-10 2010-04-22 Taisho Pharmaceutical Co Ltd インドール又はインドリン誘導体
CN103588771A (zh) * 2013-01-15 2014-02-19 苏州云轩医药科技有限公司 具有刺猬通路拮抗剂活性的嘧啶类抗肿瘤化合物
WO2014160177A2 (en) * 2013-03-13 2014-10-02 Exelixis, Inc. Quinazoline inhibitors of pi3k
WO2016123151A1 (en) * 2015-01-26 2016-08-04 University Of Washington Bumped kinase inhibitor compositions and methods for treating cancer
CN109790156A (zh) * 2016-07-04 2019-05-21 苏州开拓药业股份有限公司 具有刺猬通路拮抗剂活性的手性杂环化合物及其制备方法和应用
CN109476664A (zh) * 2017-05-17 2019-03-15 乐高化学生物科学股份有限公司 作为自分泌运动因子抑制剂的新型化合物和包含其的药物组合物
CN107245074A (zh) * 2017-06-20 2017-10-13 牡丹江医学院附属红旗医院 用于治疗脑梗死的化合物及其制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113493453A (zh) * 2020-04-07 2021-10-12 江苏恒瑞医药股份有限公司 稠合芳香环类衍生物、其制备方法及其在医药上的应用
CN113493453B (zh) * 2020-04-07 2023-06-16 江苏恒瑞医药股份有限公司 稠合芳香环类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
CN114423759B (zh) 2023-10-20
WO2021078227A1 (zh) 2021-04-29
TW202128686A (zh) 2021-08-01

Similar Documents

Publication Publication Date Title
KR101829940B1 (ko) 프탈라지논 케톤 유도체, 이의 제조방법, 및 이의 약학적 용도
CN115244056A (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
EP3556761B1 (en) Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof
EP4166555A1 (en) Pyridine-pyrimidine derivative, preparation method therefor and pharmaceutical use thereof
EP3950690A1 (en) Pyrroloheterocyclic derivative, preparation method therefor, and application thereof in medicine
CN114423760A (zh) 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用
CN114423759B (zh) 稠合杂芳基类衍生物、其制备方法及其在医药上的应用
CN113825757B (zh) 取代的稠合双环类衍生物、其制备方法及其在医药上的应用
CN113874354B (zh) 吡啶酮类衍生物、其制备方法及其在医药上的应用
JPWO2003070730A1 (ja) ピロロピリミジン誘導体
US20220213119A1 (en) Thienoheterocyclic derivative, preparation method therefor and medical use thereof
WO2020125513A1 (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
CN111320633A (zh) 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途
CN114728167B (zh) 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法
JP2022511236A (ja) 置換キナゾリノン誘導体、及びｍＧｌｕＲ４のポジティブアロステリック調節剤としてのその使用
CN114437116A (zh) 杂环化合物及其制备方法、药物组合物和应用
CN111153891B (zh) 一种取代苯并咪唑类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用
CN113493453B (zh) 稠合芳香环类衍生物、其制备方法及其在医药上的应用
CN115772161A (zh) 含氮杂芳基化合物、其制备方法及其在医药上的应用
CN115867552A (zh) 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2022174765A1 (zh) 作为Wee-1抑制剂的稠环化合物
WO2021185238A1 (zh) 稠合二环类衍生物、其制备方法及其在医药上的应用
CN112457296A (zh) 嘧啶类化合物及其制备方法
CN111718351B (zh) 含氧取代吡唑并嘧啶化合物和药物组合物及其应用
WO2022135390A1 (zh) 己酮糖激酶抑制剂及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant